Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04958993 | A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 7 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT02963610 | Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Dec 30, 2021 |
| clinicaltrials |
| NCT00372073 | Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer | terminated | Phase 2 | 187 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 22, 2021 | clinicaltrials |
| NCT00885963 | A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer | terminated | Phase 2 | 62 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 22, 2021 | clinicaltrials |
| NCT00960297 | Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC | terminated | Phase 2 | 4 | SCRI Development Innovations, LLCOTHER | 1 | Dec 6, 2021 | clinicaltrials |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | terminated | Phase 1 / Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 24, 2021 | clinicaltrials |
| NCT01741155 | Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) | terminated | Phase 2 | 34 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 13, 2021 | clinicaltrials |
| NCT02387216 | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC(SHERLOC) | terminated | Phase 2 | 153 | Elevation OncologyINDUSTRY | 6 | Oct 12, 2021 | clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | terminated | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT01108666 | Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 7 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | terminated | Phase 1 / Phase 2 | 65 | PfizerINDUSTRY | 4 | Jun 10, 2021 | clinicaltrials |
| NCT02621333 | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma | terminated | Phase 2 | 280 | Henan Cancer HospitalOTHER_GOV | 1 | May 12, 2021 | clinicaltrials |
| NCT03644823 | Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC(COM-IT-1) | terminated | Phase 2 | 21 | Oslo University HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02132598 | Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases | terminated | Phase 2 | 5 | Liza Villaruz, MDOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT03256721 | Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC | terminated | Phase 2 | 37 | Fuzhou General HospitalOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT02485652 | Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung | terminated | Phase 2 | 162 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 10 | Jan 22, 2021 | clinicaltrials |
| NCT03382899 | Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer(Cypress 1) | terminated | Phase 2 | 101 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04170959 | The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC(RADFORMIN) | terminated | Phase 2 | 3 | ethisch.comite@uza.beOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT00760929 | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). | terminated | Phase 2 | 171 | Hoffmann-La RocheINDUSTRY | 11 | Jan 5, 2021 | clinicaltrials |
| NCT01268059 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 99 | MedImmune LLCINDUSTRY | 7 | Dec 23, 2020 | clinicaltrials |
| NCT00794417 | A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Regeneron PharmaceuticalsINDUSTRY | 2 | Dec 10, 2020 | clinicaltrials |
| NCT04044170 | Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | terminated | Phase 2 | 5 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 2 | Nov 17, 2020 | clinicaltrials |
| NCT03302247 | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | terminated | Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT02318368 | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label(FOCAL) | terminated | Phase 2 | 10 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Oct 22, 2020 | clinicaltrials |
| NCT01188707 | A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 5 | Herlev HospitalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02642939 | Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | terminated | Phase 2 | 3 | Check, Jerome H., M.D., Ph.D.INDIV | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03382912 | Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer(Cypress 2) | terminated | Phase 2 | 52 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT02147990 | Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer(NSCLC) | terminated | Phase 2 | 318 | Clovis Oncology, Inc.INDUSTRY | 12 | Aug 12, 2020 | clinicaltrials |
| NCT01526928 | Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | terminated | Phase 1 / Phase 2 | 612 | Clovis Oncology, Inc.INDUSTRY | 4 | Aug 4, 2020 | clinicaltrials |
| NCT02193152 | Pazopanib in Molecularly Selected Patients With Advanced NSCLC | terminated | Phase 2 | 16 | Washington University School of MedicineOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT01857271 | Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer(EVENT) | terminated | Phase 2 | 3 | Albert Einstein College of MedicineOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT03411473 | Study of AGEN1884 With Pembrolizumab in 1L NSCLC | terminated | Phase 2 | 2 | Agenus Inc.INDUSTRY | 2 | Jun 2, 2020 | clinicaltrials |
| NCT00420732 | Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer | terminated | Phase 2 | 6 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01774578 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | terminated | Phase 2 / Phase 3 | 135 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT02452463 | Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy | terminated | Phase 2 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | terminated | Phase 2 / Phase 3 | 9 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03574818 | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 | terminated | Phase 2 | 1 | Montefiore Medical CenterOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT01717482 | Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer | terminated | Phase 2 | 6 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02469701 | Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease | terminated | Phase 2 | 10 | howard safranOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02117024 | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | terminated | Phase 2 | 66 | Heat BiologicsINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03232892 | Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer | terminated | Phase 2 | 1 | University of California, San FranciscoOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00923273 | Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2019 | clinicaltrials |
| NCT02770014 | Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer | terminated | Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT02920450 | Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) | terminated | Phase 1 / Phase 2 | 3 | University of FloridaOTHER | 1 | Oct 4, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Feb 25, 2022source: clinicaltrials